SARS-CoV-2 nucleocapsid protein (Wuhan-Hu-1) (N)

The SARS-CoV-2 nucleocapsid (N) protein is a critical structural component of the virus, primarily responsible for packaging the positive-sense single-stranded RNA genome into a helical ribonucleoprotein (RNP) complex [2, 3, 8]. Beyond its structural role in virion assembly, the N protein is a multifunctional phosphoprotein that significantly enhances the efficiency of viral replication and transcription [4, 6, 8]. It also plays a pivotal role in modulating the host's innate immune response by acting as an antagonist to interferon production and RNA interference pathways [2, 3, 4]. Clinically, the N protein is an immunodominant antigen, making it a primary target for diagnostic assays, including rapid antigen tests and serological monitoring [6, 7, 14]. As a therapeutic target, researchers are exploring small molecules like K31 and repurposed drugs that can disrupt its RNA-binding activity or inhibit its ability to undergo liquid-liquid phase separation, which is essential for viral life cycle processes [12, 13, 17, 19]. However, its role in promoting hyperinflammation through NLRP3 inflammasome activation presents a challenge for therapeutic intervention [2, 8, 16]. The protein's high conservation across variants makes it an attractive target for broad-spectrum antiviral development, although its structural disorder poses significant design hurdles [4, 14, 19]. Monitoring N protein levels in serum has also emerged as a valuable biomarker for predicting disease severity and treatment response in hospitalized patients [7, 10, 15].

Other names

NucleoproteinN proteinNCAPNCAP_SARS22019-nCoV nucleocapsid protein

Inhibition of RNA binding to the N-terminal domain, disruption of ribonucleoprotein complex assembly, and interference with liquid-liquid phase separation required for viral replication.